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ABSTRACT
Objective: To determine whether the administration of tamsulosin, as adjunctive medical therapy, increases the 
efficacy of one session of extracorporeal shock wave lithotripsy (ESWL) to treat renal stones. Material & Method: A 
prospective randomized placebo controlled study enrolled 21 patients. They underwent a single ESWL session to treat 
solitary radiopaque renal stones 4 to 20 mm in diameter. After ESWL, the study group (11) received 0,4 mg tamsulosin 
daily and the control group (10) received placebo until stone clearance or a maximum period of 8 weeks. The primary 
endpoint was stone-free rate and parameters were stone size and clearance time. Results: The overall stone-free rate 
was better in the study group than in the control group (90,9% vs. 60,0%). The clearance time after 2, 4, 6 and 8 weeks 
was greater in the study group than in the control group (36,4%; 63,6%; 72,7% and 90,9% vs 30,0%; 50,0%; and 
60,0% respectively) but statistically insignificant. Conclusion: Clinically, the results of our study have demonstrated 
that tamsulosin therapy, as an adjunctive medical therapy after ESWL, is more effective than lithotripsy alone for the 
treatment of patients with renal stones.
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INTRODUCTION
Urinary tract stone disease is the third most 
common disease from the entire urinary tract 
abnormalities after urinary tract infections and 
1
prostate disorders.  In the United States the prevalence 
2
of urolithiasis is estimated at 10% to 15%.  In 
Indonesia, urinary tract stone disease still holds the 
largest share of total patients in urology clinic, with the 
3
precise incidence still undetermined.
The discovery of ESWL (Extracorporeal Shock 
Wave Lithotripsy) is a revolutionary change in the 
therapy of kidney stones, compared to the main 
previous option of surgery. Twenty years after the 
introduction of ESWL and endourology, such as URS 
(ureterorenoscopy) and PNL (percutaneous 
nephrolithotripsy), the management of calyceal stones 
has changed drastically. Where in the era of 1970-
1980s, open surgery was an option, it is rarely done 
today. Minimally invasive procedures are chose 
because of fewer complications compared to open 
4
surgery.
ESWL is a non-invasive technology, first used in 
1980. Thereafter ESWL has been used extensively 
5
throughout the world.  ESWL is preferred due to its 
non-invasive nature and limited morbidity compared 
to open surgery or other more invasive techniques. But 
in a setting of large, hard and multiple stones, ESWL 
may require multiple sessions, or surgery is required if 
complications arise, such as obstruction due to stone 
6
fragments.  American Urological Association (AUA) 
have published guidelines for the management of 
ureteric stones and kidney stones, in which stones of 
7
less than 20 mm can be subjected to ESWL.  
Studies on the use of tamsulosin on ureteral stone 
are various, especially for distal ureteric stones, 
considering 1-adrenergic receptors are the most 
numerous in the distal ureter.
36
The concept of using 1-adrenergic receptor 
antagonists as adjuvant therapy in ESWL therapy has 
been studied several times. A study comparing use of 
tamsulosin after ESWL of ureteral stones with control 
group without tamsulosin revealed the stone-free rate 
was 70,8% in tamsulosin group and 33,3% in group 
8
without tamsulosin.
However, studies on tamsulosin as adjuvant 
therapy after ESWL on kidney stone are still limited. 
Gravina et al (2005), who conducted a study on the 
efficacy of tamsulosin after ESWL of kidney stones 
revealed, that after 12 weeks the stone-free rate was 
78,5%, compared to the group without tamsulosin 
60%. Effect of tamsulosin was better on larger stones 
9
(> 20 mm).
OBJECTIVE
To determine stone-free rate and time to stone-free 
status in kidney stones patients subjected to ESWL 
with and without tamsulosin administration.
MATERIAL & METHOD
This study was a quasi-experimental study 
performed from January to July 2010. The samples in 
this study were patients diagnosed with kidney stones 
who performed ESWL in Soetomo Hospital Surabaya. 
Samples were randomly allocated into 2 groups, 10 
individuals each. In Group 1 (tamsulosin group), after 
ESWL the patients took tamsulosin 0,4 mg once daily 
for 8 weeks, whereas in group 2 (control group) 
patients also underwent ESWL but received no 
adjuvant tamsulosin. 
Criteria for inclusion in this study were (1) 
Patients diagnosed with calyx stone with size > 5 mm 
and < 20 mm, (2) Age more than 18 years, (3) Serum 
creatinine below 1,7 mg/dL, (4) Normal routine blood 
tests, hemostatic function, and electrolytes, (5) 
Radiopaque stones, (6) Lower calyx stones, 
infundibulopelvic angle of more than 70º, 
infundibulum width more than 5 mm, and length of 
infundibulum less than 3 cm, (7) Subjected to IVP 
examination.
Five of 21 subjects in this study required repeat 
th
ESWL because until end of the 8  week of obser-
vation, there was still residual stone > 3 mm. No 
subject dropped out or developed complications that 
required treatment or surgery. Homogeneity test on 
stone diameter, age, gender, and location of the stone, 
showed no significant difference. Statistical analysis 
was performed descriptively and analytically. 
Difference in stone-free rate between treatment and 
control group was analyzed using two-layer Chi 
Square test. Observations were made at weeks 2, 4, 6, 
and 8.
RESULTS
The youngest subject was 19 years old while the 
oldest was 65 years old. The average age of 21 patients 
enrolled ranged 12,055 ± 49,14 years. The median age 
of the patients was 52 years. Most of the samples 
(57,1%) were male (Table 1). Stone location was 
mostly in the lower pole (57,1%) and a majority of 
stones was on the right side (71,4%).
Table 1. Characteristics of sex, stone location, and position.
57,1
42,9
100,0
57,1
33,3
9,5
100,0
71,4
28,6
100,0
Categories Freq %
Male
Female 
Total
Lower
Middle
Upper
Total
Right 
Left
Total
12
9
21
12
7
2
21
15
6
21
Sex
Store location 
Position (right 
and left)
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Table 2. Comparison of stone-free rate in week 2.
Stone-free
Incidence Tamsulosin 
(n = 11)
No Tamsulosin 
(n = 10)
Total 
Group 
4
36,4%
7
63,6%
11
52,4%
3
30,0%
7
70,0%
10
47,6%
7
33,3%
14
66,7%
21
100,0%
Stone-free
No  Stone-free 
Total
2
c
 
Sig.
0,000
1,000
Table 4. Comparison of stone-free rate in week 6.
Stone-free
Incidence Tamsulosin 
(n = 11)
No Tamsulosin 
(n = 10)
Total 
Group 
8
72,7%
3
27,3%
11
52,4%
6
60,0%
4
40,0%
10
47,6%
14
66,7%
7
33,3%
21
100,0%
Stone-free
No Stone-free 
Total
2
c
 
Sig.
0,024
0,659
Table 3. Comparison of stone-free rate in week 4.
Stone-free
Incidence Tamsulosin 
(n = 11)
No Tamsulosin 
(n = 10)
Total 
Group 
7
63,6%
4
36,4%
11
52,4%
5
50,0%
5
50,0%
10
47,6%
12
57,1%
9
42,9%
21
100,0%
Stone-free
No Stone-free 
Total
2
c
 
Sig.
0,036
0,670
Table 5. Comparison of stone-free rate in week 8.
Stone-free
Incidence Tamsulosin 
(n = 11)
No Tamsulosin 
(n = 10)
Total 
Group 
10
90,9%
1
9,1%
11
52,4%
6
60,0%
4
40,0%
10
47,6%
16
76,2%
5
23,8%
21
100,0%
Stone-free
No Stone-free 
Total
2
c
 
Sig.
1,318
0,149
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Table 6. Comparison of stone-free rates based on stone diameter in week 2.
Tamsulosin 
(n = 11)
No Tamsulosin 
(n = 10)
Group 
Total Diameter 
categories
Count
Expected count
% within week 2
Count
Expected count
% within week 2
Count
Expected count
% within week 2
Count
Expected count
% within week 2
Count
Expected count
% within week 2
4
3,5
57,1%
3
3,5
42,9%
7
7,0
50,0%
4
4,0
57,1%
4
4,0
57,1%
3
3,5
42,9%
4
3,5
57,1%
7
7,0
50,0%
3
3,0
42,9%
3
3,0
42,9%
7
7,0
100,0%
7
7,0
100,0%
14
14,0
100%
7
7,0
100,0%
7
7,0
100,0%
Stone 
free
Stone
present
Stone
present
Week 2
Total
Week 2
Total
< 10mm
> 10mm
nd
In the 2  week of observation (Table 2) clinical 
stone-free rate in tamsulosin group was better than 
control group (36,4% vs 30%), but not statistically 
significant (p = 1,000).
Clinical manifestations of tamsulosin were 
increasingly observable in week 4 (Table 3), where the 
stone-free rate reached 63,6%. It increased almost two 
fold compared to week 2, but significance was still 
higher than 0,05 (p = 0,670), which concluded there 
was no statistically significant difference between the 
two groups.
Stone-free rate in week 4 (table 7) in both groups 
had clinically remarkable increase (85,7% vs 71,4%) 
In week 6 (table 8), stone-free rate in tamsulosin 
group and control group was the same, 85,7%, for 
stone diameter < 10 mm. The significance value 
obtained was 1,000 (p > 0,05), but showing no 
significant difference in stone-free rates in tamsulosin 
group and control group for stone diameter < 10 mm.
For stone size > 10 mm statistical calculation for 
the two groups was not significant (p = 0,429), but the 
clinical significance of tamsulosin appeared better 
than that in control group. This was demonstrated by 
the increased stone-free rate (50% vs 0%).
Observations by the end of week 8 (table 9), 
showed the effect of tamsulosin therapy on stone size > 
10 mm was better than in controls, as shown by 
39
The increase of stone-free rate on observation week 6 
(Table 4), both in tamsulosin group and control group, 
was still observed (72,7% vs 60%). Tamsulosin group 
was clinically better than the control group. Significance 
value obtained in week-6 was 0,659, not much different 
from the results in week 4 and remained not statistically 
significant.
Observations until the end of week 8 (Table 5) revealed 
that the therapeutic effects of tamsulosin were clearly 
visible when compared with the control group. Stone-free 
rate of tamsulosin group increased compared to week 6, 
while the control group remained (90,9% vs 60%). But 
based on the calculation this difference remained statistically 
significant (p = 0,149).
The observation in week 2 (table 6) revealed that 
stone-free rate from both groups stratified based on 
stone diameter, for stone size < 10 mm remained better 
in the tamsulosin group than in control group (57,1% 
vs 42,9%). However, those with stone diameter > 10 
mm could not be analyzed because there was no 
change. Difference in stone-free rate of stones < 10 
mm for both groups was not significant (p = 1,000).
for stone with of size < 10 mm compared with that in 
week 2, but the significance value between tamsulosin 
groups compared to control group was not high, which 
was 1,000 (p > 0,05).
Observation in week 4 for stone size > 10 mm 
showed that stone-free rate in tamsulosin group 
increased compared to controls (25% vs 0%), with 
significance value of 1,000. There was still no 
statistically significant difference between the two 
groups.
Tamsulosin 
(n = 11)
No Tamsulosin 
(n = 10)
Group 
Total 
Table 7. Comparison test of stone-free rates by stone diameter in week 4.
Diameter 
categories
Count
Expected count
% within week 4
Count
Expected count
% within week 4
Count
Expected count
% within week 4
Count
Expected count
% within week 4
Count
Expected count
% within week 4
Count
Expected count
% within week 4
6
5,5
54,5%
1
1,5
33,3%
7
7,0
50,0%
1
,6
100,0%
3
3,4
50,0%
4
4,0
57,1%
5
5,5
45,5%
2
1,5
66,7%
7
7,0
50,0%
0
,4
0%
3
2,6
50,0%
3
3,0
42,9%
11
11,0
100,0%
3
3,0
100,0%
14
14,0
100,0%
1
1,0
100,0%
6
6,0
100,0%
7
7,0
100,0%
Stone 
free
Stone
present
Stone
present
Stone
present
Week 4
Total
Week 4
Total
< 10mm
> 10mm
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Tamsulosin 
(n = 11)
No Tamsulosin 
(n = 10)
Group 
Total 
Table 8. Comparison of stone-free rates based on stone diameter in week 6.
Diameter 
categories
Count
Expected count
% within week 6
Count
Expected count
% within week 6
Count
Expected count
% within week 6
Count
Expected count
% within week 6
Count
Expected count
% within week 6
Count
Expected count
% within week 6
6
60,0
50,0%
1
1,0
50,0%
7
7,0
50,0%
2
1,1
100,0%
2
2,9
40,0%
4
4,0
57,1%
6
60,0
50,0%
1
1,0
50,0%
7
7,0
50,0%
0
,9
,0%
3
2,1
60,0%
3
3,0
42,9%
12
12,0
100,0%
2
2,0
100,0%
14
14,0
100,0%
2
2,0
100,0%
5
5,0
100,0%
7
7,0
100,0%
Stone 
free
Stone
present
Stone
present
Stone
present
Week 6
Total
Week 6
Total
< 10mm
> 10mm
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increased stone-free rate to 100%, while in control 
group remained 85,7%. This difference was not 
statistically significant (p > 0,05).
Tamsulosin 
(n = 11)
No Tamsulosin 
(n = 10)
Group 
Total 
Table 9. Comparison of stone-free rates based on stone diameter in week 8.
Diameter 
categories
Count
Expected count
% within week 8
Count
Expected count
% within week 8
Count
Expected count
% within week 8
Count
Expected count
% within week 8
Count
Expected count
% within week 8
Count
Expected count
% within week 8
7
6,5
53,8%
0
,5
0,0%
7
7,0
50,0%
3
1,7
100,0%
1
2,3
25,0%
4
4,0
57,1%
6
6,5
46,2%
1
,5
100,0%
7
7,0
50,0%
0
1,3
0,0%
3
1,7
75,0%
3
3,0
42,9%
13
13,0
100,0%
1
1,0
100,0%
14
14,0
100,0%
3
3,0
100,0%
4
4,0
100,0%
7
7,0
100,0%
Stone 
free
Stone
present
Stone
present
Stone
present
Week 8
Total
Week 8
Total
< 10mm
> 10mm
Changes in stone-free rate in tamsulosin group 
were also seen on stone size > 10 mm (75% vs 0%), 
data showed that tamsulosin administration was 
clinically beneficial. However, this was not supported 
by statistical significance calculations. Significance 
value of 0,143 (p > 0,05) indicated no significant 
difference between the two groups.
DISCUSSION
Researchers have reported study results of 
medications to minimize intrinsic factors that cause 
ureteric narrowing (ureteric peristalsis, spasm, and 
edema), thus increasing ureteric stone expulsion. 
Borghi and Porpligia reported a combination of 
nifedipine and corticosteroids improved mean time to 
expulsion of ureteric stones. Furthermore, the use of -
1 adrenergic antagonists for ureteral stones has been 
widely studied. In this study, researchers used 
tamsulosin, because it works well as a selective 
antagonist of -1a and -1d adrenoceptors, does not 
9
require dose titration and have minimal side effects.
Urinary tract stone disease occurs more often in 
adult men than adult women. With a wide range of 
indicators, the incidence of urinary tract stones in men 
ranged from 2 to 3 times more frequently than in 
10
women.  The sample of this study showed that men 
had 1,3 times more susceptibility than women. It 
remains unclear why the stone tends to grow in lower 
calyx, although accumulation of stone fragments in 
this site is very likely related to gravity.
Time to stone-free state is one important indicator 
but is rarely measured in previous studies. The 
difficulty in this case is partly because the patients 
included in samples could not properly record the time 
 9
and number of fragments expulsed,  and also due to 
the costs and effects of X-ray radiation and ultrasound 
scanning as a means of evaluating treatment results. 
Therefore, the remaining source that could be used to 
assess stone-free event was the regular intervals when 
the patient made a visit, i.e., in weeks 2, 4, 6, and 8 
post-ESWL.
In this study there were no statistically significant 
difference in all comparisons of  time to stone-free 
status in tamsulosin group compared to control group 
in week 2 (p = 1,0), week 4 (p = 0,670), week 6 (p = 
0,659) , and week 8 (p = 0,659). Observation to groups 
with and without tamsulosin regarding stone diameter, 
with diameter of < 10 mm and 11-20 mm, showed no 
significant difference in all observations from week 2 
to 8, both in groups with stone diameter of < 10 mm 
and 11-20 mm. These results differed from previous 
studies. Seitz (2009) stated in his collaborative review 
that 19 out of 20 studies related to -blockers with 
stones > 5 mm (14 studies on ureteric stones, 3 studies 
on kidney stones) concluded that there was a 
11
significant advantage in stone expulsion rates.  
Gravina (2005) and Bhagat (2007) in their research 
findings also stated that there were significant 
9,12
differences in stone with a diameter of > 10 mm.
The results of this study showed that tamsulosin 
0,4 mg as adjuvant therapy after ESWL on kidney 
stones in treatment group provided higher Stone-Free 
Rate (SFR) compared to the control group (90,9% vs 
60%). Up to the end of week 8, Naja (2008) in similar 
studies found similar results in the administration of 
tamsulosin after ESWL for kidney stones in week 12 
13
(94,1% vs 84,6%; p = 0,14).  This result is different 
from other existing studies. Gravina (2005) reported 
the success rate of one ESWL session for kidney stones 
with tamsulosin, in which the success was obtained in 
week 12 (78% vs 60%, p = 0,04), while Bhagat (2007) 
also reported significant results with tamsulosin 
administration for 4 weeks (96,6% vs 79,3%; p = 
9,12
0,04).
In general, previous studies showed better 
outcome of kidney stones treated with ESWL receiving 
tamsulosin as adjuvant therapy. In three studies, the 
clearance rate was higher after tamsulosin for 4 weeks 
12,13
compared to 12 weeks.  Therefore, it can be assumed 
that larger fragments in tamsulosin group were 
expulsed faster, producing better success rate than in 
control group, requiring no further ESWL sessions.
The results of time to stone-free in this study was 
not significant when compared to previous studies. 
This might be caused by the mean diameter of the 
stone. The mean stone diameter in this study was 8,91 ± 
2,914 mm in tamsulosin group and 8,70 ± 2,003 mm in 
control group. Whereas, in previous studies by Gravina 
et al (2005), Bhagat et al (2007) and Naja et al (2008), 
stones in diameter of < 10 mm, the success rate in 
tamsulosin groups was not significant compared to that 
9,12,13
in control group.  Another possible cause of the 
insignificance in this study was the location of the 
stone. The locations of stone samples in this study were 
mostly in inferior calyx (12/21, 60%). Two of the three 
previous studies by Gravina et al (2005) and Naja et al 
41
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(2008) did not use stones in inferior calyx with the 
reason that the location did not have a beneficial effect 
9,13
from medications.
Stone-Free Rate (SFR) for the inferior calyx stone 
varied between 67,8% (for < 10 mm), 54,6% (11-20 
8
mm) and 28,8% (> 20 mm).  Inferior calyx stone is a 
complex problem in the treatment of urinary tract 
stones with ESWL. First, many kidney stones 
originates from inferior calyx and its clearance rate 
tends to be lower compared to stones in other location. 
Second, stone fragments after ESWL, although 
originating from other calyces, tend to gather in the 
14
inferior calyx which is likely influenced by gravity.
Anatomical-geometrical factor of the inferior 
calyx is also referred to as an important prognostic 
factor affecting clearance. Prognostic factors in 
question are infundibulo-pelvic angle, infundibular 
15
width and length.  Sampaio (1997) states that the 
favorable anatomical features of inferior calyx are 
infundibulo-pelvic angle of 90º or more, infundibular 
width of > 5 mm, and length < 30 mm. Sorenson and 
Chandhoke (2002) mentions that infundibulo-pelvic 
16
angle is favorable if > 70º,  while the width and length 
of infundibulum are similar to those in previous 
research.
Unfortunately, relationship between anatomical-
geometrical factors of inferior calyx and clearance rate 
is still being debated in several studies. A 
comprehensive overview conducted by Danuser 
(2007) mentions that seven of the 11 studies found no 
relationship between infundibulum width and stone 
clearance. Positive relationship between long 
infundibulum and SFR was found in 6 of 12 studies, 
while those that found correlation between 
infundibulo-pelvic angle and SFR comprised 5 from 
12 studies. Danuser, therefore, suggested that the 
relationship between anatomical-geometrical factors 
17
of calyx inferior with SFR is still not clear.  No strong 
evidence base as a reference for clinical practice exists 
that helps to predict the success of ESWL for inferior 
14
calyx.
CONCLUSION
The results of this study indicate that clinical 
administration of tamsulosin as adjuvant therapy after 
ESWL is more effective than ESWL alone for 
treatment of kidney stones.
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